Sodium Chloride (NaCl) 0.9 %
DrugKeep vein open rate
Other names: Restricted
NCT Number: NCT07188766
Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC.
This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles.
We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Not applicable
King Fahd Hospital of the University, Dammam, Eastern Province, Saudi Arabia
This study is a prospective, non-inferiority, open-label, multicenter randomized-controlled trial (RCT) conducted in the emergency departments (EDs) of tertiary care hospitals in Saudi Arabia. The primary objective is to compare two fluid management strategies- restrictive (intervention) vs. liberal (control) in adult sickle cell disease (SCD) patients hospitalized for VOC. The study evaluates whether a restrictive fluid approach is non-inferior to a liberal strategy in terms of pain resolution, hospitalization duration, and other clinical outcomes.
Patients will be randomized upon ED admission, and their assigned fluid regimen will be administered within the first hour. Clinical teams will monitor outcomes throughout hospitalization or up to 28 days post-enrollment.
Study Population
Consent Model: A priori informed written consent will be obtained from conscious, coherent patients or substitute decision-makers.
Presenting with VOC requiring hospitalization.
Numeric Pain Rating Scale (NPRS) >5
Willingness to participate and provide informed consent.
Cardiac/Renal Conditions:
Congestive heart failure (CHF) or symptomatic systolic heart failure.
Patients with ESRD on chronic dialysis.
Hemodynamic Instability:
Shock (SBP <100 mmHg or MAP <65) with hypoperfusion signs.
Other Exclusions:
Known/suspected pregnancy.
Prior enrollment in this trial within the last 30 days.
Concurrent enrollment in another trial affecting fluid management.
Inability to obtain IV access.
Trial Intervention
A screening log will track eligible vs. randomized patients.
Efforts will be made to obtain consent immediately from the patient or surrogate.
B. Control (Liberal) 20 mL/kg IV bolus (NS or LR over 1 hour) + maintenance fluids (1.5-2 mL/kg/day).
Initiation: Both regimens starts within 1 hour of ED admission and continue until ED discharge.
Hospitalized Patients:
Pain scores (NPRS) recorded at 24, 48, and 72 hours. Total fluid intake documented at hospital discharge.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Keep vein open rate
Other names: Restricted
Time frame: Baseline (within 30 minutes post admission), 1 hour, then hourly until ED discharge or 24- 48- and 72-hours post-admission ( for admitted patients)
Measured using the Numeric Pain Rating Scale (NPRS)
Time frame: up to 4 hours
NPRS score of ≤5
Time frame: at least 4 hours
time elapsed from ED admission to ED discharge or admit to the wards
Time frame: within 24 hours of ED admission
Proportion of participants requiring inpatient admission
Time frame: up to 4 hours
Total opioid consumption during acute VOC episode
Time frame: within 72 hours post ED discharge
Percentage of patients who revisited the emergency department
Time frame: within 28 days post-enrollment
number of patients who died
Time frame: up to 7 days
total number of patients who encountered allergic reactions, respiratory distress, pulmonary edema, and acute chest syndrome, development of tachypnea, hypoxia, cough, crackles on auscultation, elevated BP, need for respiratory support, heart failure (worsening of tachycardia, hepatomegaly, peripheral edema, and allergic reactions (urticaria, angioedema, hypotension, wheezing)
Contact information is provided by the study sponsor or research team.
Laila Perlas Asonto, RN
CONTACT
Mohammed S Alshahrani, MD
CONTACT
Imam Abdulrahman Bin Faisal University
Other
Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive Versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)
Acronym: FLASC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03655223
17 Alpha-Hydroxylase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT05952817
Anemia, Anemia, Hemolytic
Jizan, Saudi Arabia
View Trial DetailsNCT06601894
Anemia, Anemia, Hemolytic
Dammam, Saudi Arabia
View Trial DetailsNCT02065596
Anemia, Anemia, Hemolytic
Cleveland, Ohio, United States
View Trial Details